logo

INTRODUCTION

The following primer discusses the use of ctDNA for monitoring the response to checkpoint inhibitors in patients with cancer. It provides the rationale for the use of this liquid-biopsy technique, a review of the data to support it, case examples illustrating its use, and practical guidance on the test. The primer also provides an off-link to a related patient education handout. We thank George Ansstas, MD, Associate Professor in the Oncology Division of Washington University School of Medicine in Saint Louis, for his contributions to this primer.

Checkpoint Inhibitor Response Monitoring: Timely Guidance Using ctDNA

STATUS: Advances in immunotherapy have ushered in a new era of oncology.

PROBLEM: At most, 20% of patients are likely to derive a sustained response from checkpoint inhibitors.[Robert 2020] Even though new therapeutic approaches are in development to address this problem, questions remain about therapeutic decision making. These include:

  • How can we know if treatment is working?
  • How quickly can we assess response?
  • How and when should treatment be sequenced or re-initiated?

SOLUTION:  Enhanced monitoring to assess response and inform decision making as early as possible. Existing tissue-based biomarkers (such as PD-L1, tumor mutational burden, etc.) are not useful for predicting the response to immunotherapy. But there is an effective approach.

Rationale for Use of Circulating Tumor Cell DNA (ctDNA)

  • Patients with cancer have more circulating DNA (segments of DNA that are released from living or dead cells) than individuals without cancer
  • This difference is related to tumorigenesis (high rate of cell death in large tumors as well as tumor aggressiveness)
  • Release of ctDNA fragments is increased at several stages of tumorigenesis, with the highest concentrations in metastatic disease (See Figure 1)
  • Therefore, measurement of ctDNA has a potential role in diagnosis, prognosis, and treatment monitoring

Figure 1. Sensitive tumor detection with ctDNA. The diagram shows tumor progression and the ability of different biopsy techniques to detect tumor burden at different time points. This illustration shows how liquid biopsy can detect low levels of tumor burden that are missed by conventional biopsy techniques (for example, at neoplastic transformation and at tumor regression after treatment). Adapted from Anmery, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons.

Why ctDNA Is Beneficial

  • ctDNA is an established liquid biopsy technique in oncology (See sidebar on ctDNA Liquid Biopsies in Oncology)
  • The Signatera® ctDNA liquid biopsy test can be used to monitor the response to checkpoint inhibitors in patients with cancer
  • The test is personalized for each patient’s own tumor mutational signature and can be used to monitor treatment response or detect disease recurrence earlier than clinical assessment and radiologic scans [Abbosh 2017]
  • The INSPIRE study demonstrated the efficacy of this test for checkpoint inhibitor response monitoring in patients treated with pembrolizumab.[Bratman 2020] For details of the INSPIRE study, click here
  • Similar results have been seen in other studies, including a study specific to melanoma and anti-PD1 therapy [Seremet 2019]
  • However, ctDNA has not been found effective in detecting or monitoring intracranial disease in the setting of melanoma [Lee 2020]

Performance Characteristics of the ctDNA Test

In the INSPIRE trial:[Bratman 2020]

  • The test identified metastatic disease in 98% of patients
  • Positive predictive value (increasing ctDNA levels in conjunction with imaging):100% for nonresponse

Not all tumors shed ctDNA equally. ctDNA levels are highest in tumors such as triple-negative breast cancer and small-cell lung cancer, whereas they are lower in thyroid cancer, melanoma, and renal cell carcinoma.[Zhang 2021; Bratman 2020] However, in the INSPIRE study, the test worked well across tumor types, suggesting that the variation in shedding does not affect the test performance for monitoring checkpoint inhibitor efficacy.

ctDNA Liquid Biopsies in Oncology

  • Liquid biopsy tests are convenient blood tests that monitor for either circulating cancer cells or ctDNA
  • Several different liquid biopsy tests are available for ctDNA monitoring. Foundation One and Guardant 360® CDx are ctDNA tests that monitor for a range of biomarkers
  • Molecular residual disease ctDNA tests
    • Signatera® test from Natera (discussed in this primer)
    • Guardant Reveal™ is a blood-only test (no tissue required) that is currently indicated for colorectal cancer

CASE SCENARIOS SHOWING APPLICATIONS OF ctDNA MONITORING

Because the ctDNA test enables more sensitive detection of response as compared with other biomarkers or imaging scans, it enables earlier informed treatment decisions. Potential clinical scenarios to illustrate its utility include the following:

Selection of an Aggressive Combination vs Single-Agent Approach
You are evaluating a 65-year-old man with lung cancer and multiple comorbidities for single-agent vs combination therapy in the first-line setting. You decide to use the single-agent approach and monitor the response with ctDNA. As shown in Figure 2, at 6 weeks you see a rise in ctDNA levels and a slight increase in tumor measurements (stable disease). Based on this lackluster response, you decide to add a second agent to the therapy. In this situation, the combination approach was effective, as shown in the drop in both ctDNA levels and target lesion measurements after the second agent was added.

Figure 2. ctDNA-guided decision making for a patient with stable disease (SD).

Determining the Treatment Course When Imaging Results Are Difficult to Interpret
You are following a 42-year-old woman with liver metastases from triple-negative breast cancer who is receiving immunotherapy. As shown in Figure 3, the target lesion appears to be growing, but the ctDNA level is dropping. You suspect that the lesion expansion is pseudoprogression, characterized by an initial increase in the size of a tumor or new lesion formation during the early stages of checkpoint inhibitor therapy.[Jia 2019] Given the drop in the ctDNA levels, you feel confident in keeping the patient on the current therapy. This decision appears correct, since both the target lesion size and ctDNA levels drop thereafter.

Figure 3. Role of ctDNA in treatment decision making in a patient with pseudoprogression.

Determining Whether Therapy Can Be Stopped
After obtaining a baseline ctDNA level, you treat a 35-year-old woman who has aggressive Stage IV melanoma with combination checkpoint inhibitor therapy. She completes 2 cycles but gets very sick with immune-related adverse effects, and you discontinue therapy. However, her scans look much improved after the discontinuation, as shown in Figure 4. At the next ctDNA check, her level is 0 MTM/mL. The clearance of the ctDNA is consistent with a molecular complete response. You decide not to reinitiate therapy and just monitor her at this point. The next few ctDNA tests continue to show clearance, suggesting a durable response.

Figure 4. ctDNA monitoring to clarify the duration and depth of response in a patient with a strong early response to combination immunotherapy.

ctDNA TESTING DETAILS

Testing Requirement
Figure 5 shows the testing process, timing, and blood and tissue requirements for ctDNA.

Figure 5. Testing process and blood and tissue requirements with the ctDNA test. FFPE = formalin-fixed paraffin embedded; H&E = hematoxylin & eosin; EDTA = ethylenediamine tetraacetic acid.

 

Billing and Coverage

  • Medicare: covered
  • Commercial insurance: manufacturer will work with the various commercial insurances
  • Cash pay rate
  • Compassionate Care program for uninsured patients or those concerned about their ability to pay (contact signaterapc@natera.com)
  • Contact for billing information: 415-918-6329

Patient Education

RESEARCH APPLICATION

The BESPOKE IO trial is a clinical research study, currently in recruitment stages, which is evaluating clinical outcomes when ctDNA is integrated into a checkpoint inhibitor treatment paradigm for colorectal cancer, melanoma, and non-small cell lung cancer [Natera 2021; clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04761783)]

REFERENCES:

Abbosh C, Birkbak NJ, Wilson GA, et al; on behalf of the TRACERx and PEACE consortia. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451.

Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873–881.

Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670.

Lee JH, Menzies AM, Carlino MS, et al. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res. 2020;26:4064-4071.

Natera, Inc. BESPOKE Study of ctDNA Guided Immunotherapy. Austin, TX: Natera, Inc. https://www.clinicaltrials.gov/ct2/show/NCT04761783.  Accessed September 20, 2021.

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11, 3801. https://doi.org/10.1038/s41467-020-17670-y

Seremet T, Jansen Y, Planken S, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17:303. doi: 10.1186/s12967-019-2051

Zhang Y, Yao Y, Xu Y, et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat Commun. 2021;12(1):11. doi: 10.1038/s41467-020-20162-8

Acknowledgment: We thank Natera for an unrestricted educational grant in support of this primer.

Copyright ©2023- - The Melanoma Nursing Initiative. All rights reserved.